lipogenesis raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-03-16 and is reviewed periodically as new material appears.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Tribenoside (Glyvenol) is a vasoprotective drug used to treat hemorrhoids. It has mild anti-inflammatory, analgesic, and wound healing properties. Tribenoside stimulates laminin α5 production and laminin-332 deposition to help repair the basement membrane during the wound healing process. It is a mixture of the α- and β-anomers. Tribenoside has been shown to induce drug hypersensitivity syndrome in association with CMV reactivation.
=== Films depicting Cold War espionage === Tinker Tailor Soldier Spy is a 2011 Cold War spy thriller adaptation of the 1974 John le Carré novel of the same name. It is set in London in the early 1970s and follows the hunt for a Soviet double agent at the top of the British secret service. The Spy Who Came In from the Cold is a 1965 British Cold War spy film based on the 1963 John le Carré novel. The film depicts a British agent's mission as a faux defector to East Germany to sow damaging disinformation about a powerful East German intelligence officer. Firefox is a 1982 film based on a Craig Thomas novel of the same name. The plot details an American plot to steal a highly advanced Soviet fighter aircraft (MiG-31 Firefox) which is capable of Mach 6, is invisible to radar, and carries weapons controlled by thought. The Hunt for Red October is a 1990 film based on the 1984 Tom Clancy novel of the same name about the captain of a technologically advanced Soviet ballistic missile submarine that attempts to defect to the United States. James Bond first appeared in 1953. While the primary antagonists in the majority of the novels were Soviet agents, the films were only vaguely based on the Cold War. The Bond movies followed the political climate of the time in their depictions of Soviets and "Red" Chinese.
On October 28, 2006, Freeman was honored at the first Mississippi's Best Awards in Jackson, Mississippi with the Lifetime Achievement Award for his work in film and theater. He received an honorary Doctor of Arts and Letters degree from Delta State University during the school's commencement exercises on May 13, 2006. In 2013, Boston University presented him with an honorary Doctor of Humane Letters degree. On November 12, 2014, he was bestowed the honor of Freedom of the City by the City of London. In 2008, Freeman was chosen as a Kennedy Center Honoree at the John F. Kennedy Center in Washington D.C. In 2011, he received the AFI Life Achievement Award in recognition of his contribution to the film industry. Those who honored Freeman included Sidney Poitier, Samuel L. Jackson, Forest Whitaker, Rita Moreno, Helen Mirren, Clint Eastwood, Cuba Gooding Jr., and Matthew Broderick. In 2012, he was awarded the Golden Globe Cecil B. DeMille Award, which recognizes lifetime achievement in the film industry. In August 2017, he was named the 54th recipient of the Screen Actors Guild Life Achievement Award for career achievement and humanitarian accomplishment. His co-star Rita Moreno from The Electric Company presented him the award in the following January. A YouGov poll conducted over the first quarter of 2026 found that 80.9% of all adults have a positive opinion of Freeman, making him the fourth most liked celebrity to date.
== Further reading == Althouse BM, Hébert-Dufresne L (October 2014). "Epidemic cycles driven by host behaviour". Journal of the Royal Society, Interface. 11 (99) 20140575. doi:10.1098/rsif.2014.0575. PMC 4235258. PMID 25100316.
Sources: en.wikipedia.org
These data suggest the possibility that lower doses of lithium orotate than lithium carbonate may achieve therapeutic brain lithium concentrations and relatively stable serum concentrations. A year later, Smith and Schou repeated the experiment at a higher dose (2 mM Li+) and found that the higher concentrations in the brain could be possibly accounted for by decreased renal function in rats treated with lithium orotate. The proponents of lithium orotate have since criticized the results by citing the fact that the dose of lithium orotate used in the study was in the toxic range. In 2022, Pacholko redid the experiment and showed lithium orotate to have a safer kidney profile than lithium carbonate, it also showed that both had an increased TSH only in females, but the increase was lower in the orotate group. The pharmacokinetics of lithium orotate in human brains is poorly documented, and there is no known mechanism by which orotate ions could alter the pharmacokinetics of dissociated lithium ions, however, lithium intake appears to be effective even at low doses, and this may account for lithium orotate's claimed effectiveness. The reason why lithium orotate is poorly studied as a medication compared to lithium carbonate is concerns raised in 1979 regarding the potential amplified renal toxicity of lithium orotate in comparison to lithium carbonate. These concerns were likely based on the results of the use of excessively high concentrations of lithium orotate in the studies.
Cefiderocolα Ceftazidime/avibactam (ceftazidime + avibactam)α Ceftolozane/tazobactam (ceftolozane + tazobactam)α Colistinα Fosfomycinα Linezolidα Meropenem/vaborbactam (meropenem + vaborbactam)α Plazomicinα Polymyxin Bα
In practise, it is used synonymously with eluate, but the term more precisely refers to the stream independent of separation taking place. Eluite – a more precise term for solute or analyte. It is a sample component leaving the chromatographic column. Eluotropic series – a list of solvents ranked according to their eluting power. Immobilized phase – a stationary phase that is immobilized on the support particles, or on the inner wall of the column tubing. Mobile phase – the phase that moves in a definite direction. It may be a liquid (LC and capillary electrochromatography, CEC), a gas (GC), or a supercritical fluid (supercritical-fluid chromatography, SFC). The mobile phase consists of the sample being separated/analyzed and the solvent that moves the sample through the column. In the case of HPLC the mobile phase consists of a non-polar solvent(s) such as hexane in normal phase or a polar solvent such as methanol in reverse phase chromatography and the sample being separated. The mobile phase moves through the chromatography column (the stationary phase) where the sample interacts with the stationary phase and is separated. Preparative chromatography – the use of chromatography to purify sufficient quantities of a substance for further use, rather than analysis. Retention time – the characteristic time it takes for a particular analyte to pass through the system (from the column inlet to the detector) under set conditions. See also: Kovats' retention index Sample – the matter analyzed in chromatography.
Sources: en.wikipedia.org
==== Contingency Management Therapy ==== Contingency Management Therapy (CMT) employs similar principles as operant behavioral conditioning, such as using incentives to reach certain goals (e.g., verified abstinence, usually in the form of urine drug testing). This form of psychotherapy has the strongest, most robust empirical support for treating drug addiction. Outpatient clients are shown to have improved medication compliance, retention, and abstinence when using voucher-based incentives. One way this is implemented is to offer take-home privileges for methadone programs. Despite its effectiveness during treatment, effects tend to wane once terminated. Additionally, the cost barrier limits its application in the clinical community.
==== MVA ==== Modified vaccinia Ankara (MVA, German: Modifiziertes Vakziniavirus Ankara) is a replication-incompetent variant of vaccinia that was developed in West Germany through serial passage. The original Ankara strain of vaccinia was maintained at the vaccine institute in Ankara, Turkey on donkeys and cows. The Ankara strain was taken to West Germany in 1953, where Herrlich and Mayr grew it on chorioallantoic membrane at LMU Munich. After 572 serial passages, the vaccinia virus had lost over 14% of its genome and could no longer replicate in human cells. MVA was used in West Germany in 1977–1980, but the eradication of smallpox ended the vaccination campaign after only 120,000 doses. MVA stimulates the production of fewer antibodies than replicating vaccines. During the smallpox eradication campaign, MVA was considered to be a pre-vaccine that would be administered before a replicating vaccine to reduce the side effects, or an alternative vaccine that could be safely given to people at high risk from a replicating vaccine. Japan evaluated MVA and rejected it due to its low immunogenicity, deciding to develop its own attenuated vaccine instead. In the 2000s, MVA was tested in animal models at much higher dosages. When MVA is given to monkeys at 40 times the dosage of Dryvax, it stimulates a more rapid immune response while still causing lesser side effects.
In 2008, Air Chief Marshal Sir Glenn Torpy Head of the Royal Air Force, for his part in Operation Telic / Operation Iraqi Freedom. Lieutenant General Sir James Dutton, Royal Marines, "in recognition of meritorious, gallant and distinguished services during coalition operations in Afghanistan". Major General Colin Boag, British Army, "in recognition of gallant and distinguished services during coalition operations in Iraq" (March 2008). Lieutenant General James Bucknall, British Army, "in recognition of gallant and distinguished services during coalition operations in Iraq" (July 2009). Major General Mohamed Elkeshky, Egyptian Army Defense, Military, Naval and Air Attaché to the United States. (2013). In 2011, Vice Admiral Tomohisa Takei, Japan Maritime Self-Defense Force, "as recognition for Takei's exceptional leadership and expertise in maturing and expanding the JMSDF and U.S. Navy partnership during his role as director of operations and plans department, JMSDF Maritime Staff Office from April 2008 to July 2010". In 2013, Lieutenant General Walter Souza Braga Netto, Brazilian Army, Military Attaché to the United States of America. "For exceptionally meritous conduct in the performance of outstanding services from March 2011 to May 2013. In 2014, Air Commodore David Best, United Kingdom Royal Air Force. "For exceptionally meritorious service as Director of Air Operations, International Security Assistance Force, from December 2010 to December 2011". In 2014, Major General Brett Cairns, Canadian Air Force, NORAD J3.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.